2025 First-Quarter reported sales growth of 2.4% to $21.9 Billion with operational growth of 4.2%* and adjusted operational growth of 3.3%* 2025 First-Quarter earnings per share (EPS) increased to $4.54 which includes the reversal of special charges and adjusted EPS increased to $2.77 or 2.2%* Significant new product pipeline progress including approval of TREMFYA in Crohn’s disease, data for RYBREVANT/LAZCLUZE overall survival in non-small cell lung cancer and icotrokinra in plaque psoriasis, and initiation of the clinical trial for a general surgery robotic system, OTTAVA Company increases Full-Year 2025 operational sales2,5 guidance to reflect the addition of CAPLYTA following the completion of the Intra-Cellular Therapies acquisition Including tariff costs, dilution from the Intra-Cellular Therapies acquisition, and updated foreign exchange, Company maintains Full-Year 2025 adjusted reported EPS4 outlook of 6.2%* growth at the mid-point
NEW BRUNSWICK, N.J.--(BUSINESS WIRE)-- Johnson & Johnson (NYSE: JNJ) today announced results for first-quarter 2025. “The power of Johnson & Johnson’s uniquely diversified portfolio was on full display this quarter, with strong operational sales growth reinforcing our confidence in 2025 guidance,” said Joaquin Duato, Chairman and Chief Executive Officer, Johnson & Johnson. “During the quarter, we fortified our position as an innovation powerhouse with major advancements across our pipeline, including TREMFYA in IBD, RYBREVANT plus LAZCLUZE in non-small-cell lung cancer, and OTTAVA, our soft tissue surgical robotic system, and further enhanced our leading neuroscience portfolio with the completion of the Intra-Cellular Therapies acquisition.”
Overall financial results
Q1
($ in Millions, expect EPS)
2025
2024
% Change
Reported Sales
$21,893
$ 21,383
2.4%
Net Earnings
$10,999
$3,255
237.9%
EPS (diluted)
$4.54
$1.34
238.8%
Q1
Non-GAAP* ($ in Millions, except EPS)
2025
2024
% Change
Operational Sales1,2
4.2%
Adjusted Operational Sales1,3
3.3%
Adjusted Net Earnings1,4
$6,706
$6,580
1.9%
Adjusted EPS (diluted)1,4
$2.77
$2.71
2.2%
Free Cash Flow6,7
~$3,400
$2,850
1
Non-GAAP financial measure; refer to reconciliations of non-GAAP financial measures included in accompanying schedules
2
Excludes the impact of translational currency
3
Excludes the net impact of acquisitions and divestitures and translational currency
4
Excludes intangible amortization expense and special items
5
Excludes COVID-19 Vaccine
6
Non-GAAP measure; defined as cash flow from operating activities, less additions to property, plant and equipment. Cash flow from operations, the most directly comparable GAAP financial measure, will be included in subsequent SEC filings.
7
First-quarter 2025 is estimated as of April 15, 2025
Regional sales results
Q1
% Change
($ in Millions)
2025
2024
Reported
Operational1,2
Currency
Adjusted
Operational1,3
U.S.
$12,305
$11,620
5.9%
5.9
-
4.4
International
9,588
9,763
(1.8)
2.1
(3.9)
1.9
Worldwide
$21,893
$21,383
2.4%
4.2
(1.8)
3.3
1
Non-GAAP financial measure; refer to reconciliations of non-GAAP financial measures included in accompanying schedules
2
Excludes the impact of translational currency
3
Excludes the net impact of acquisitions and divestitures and translational currency
Segment sales results
Q1
% Change
($ in Millions)
2025
2024
Reported
Operational1,2
Currency
Adjusted
Operational1,3
Innovative Medicine
$13,873
$13,562
2.3%
4.2
(1.9)
4.4
MedTech
8,020
7,821
2.5
4.1
(1.6)
1.3
Worldwide
$21,893
$21,383
2.4%
4.2
(1.8)
3.3
1
Non-GAAP financial measure; refer to reconciliations of non-GAAP financial measures included in accompanying schedules
2
Excludes the impact of translational currency
3
Excludes the net impact of acquisitions and divestitures and translational currency
First-Quarter 2025 segment commentary:
Operational sales* reflected below excludes the impact of translational currency.
Innovative Medicine
Innovative Medicine worldwide operational sales grew 4.2%* driven primarily by DARZALEX, CARVYKTI, ERLEADA, and RYBREVANT/LAZCLUZE in Oncology, TREMFYA and SIMPONI/SIMPONI ARIA in Immunology, SPRAVATO in Neuroscience, and XARELTO in Cardiovascular/Metabolism/Other. Growth was partially offset by an approximate (810) basis points impact from STELARA in Immunology.
MedTech
MedTech worldwide operational sales grew 4.1%*, with net acquisitions and divestitures positively impacting growth by 2.8%. Growth was driven primarily by Abiomed in Cardiovascular and wound closure products in General Surgery. Growth was partially offset by Spine, Sports & Other in Orthopaedics.
Full-year 2025 guidance:
Johnson & Johnson does not provide GAAP financial measures on a forward-looking basis because the company is unable to predict with reasonable certainty the ultimate outcome of legal proceedings, unusual gains and losses, acquisition-related expenses, and purchase accounting fair value adjustments without unreasonable effort. These items are uncertain, depend on various factors, and could be material to Johnson & Johnson's results computed in accordance with GAAP.
($ in Billions, except EPS)
April 2025
January 2025
Adjusted Operational Sales1,2,5
Change vs. Prior Year / Mid-point
2.0% – 3.0% / 2.5%
2.0% – 3.0% / 2.5%
Operational Sales2,5 / Mid-point
Change vs. Prior Year / Mid-point
$91.6B – $92.4B / $92.0B
3.3% – 4.3% / 3.8%
$90.9B – $91.7B / $91.3B
2.5% – 3.5% / 3.0%
Estimated Reported Sales3,5/ Mid-point
Change vs. Prior Year / Mid-point
$91.0B – $91.8B / $91.4B
2.6% – 3.6% / 3.1%
$89.2B – $90.0B / $89.6B
0.5% – 1.5% / 1.0%
Adjusted Operational EPS (Diluted)2,4 / Mid-point
Change vs. Prior Year / Mid-point
$10.50 – $10.70 / $10.60
5.2% – 7.2% / 6.2%
$10.75 – $10.95 / $10.85
7.7% – 9.7% / 8.7%
Adjusted EPS (Diluted)3,4 / Mid-point
Change vs. Prior Year / Mid-point
$10.50 – $10.70 / $10.60
5.2% – 7.2% / 6.2%
$10.50 – $10.70 / $10.60
5.2% – 7.2% / 6.2%
1
Non-GAAP financial measure; excludes the net impact of acquisitions and divestitures
2
Non-GAAP financial measure; excludes the impact of translational currency
3
Calculated using Euro Average Rate: April 2025 = $1.10 and January 2025 = $1.04 (Illustrative purposes only)
4
Non-GAAP financial measure; excludes intangible amortization expense and special items
5
Excludes COVID-19 Vaccine
Other modeling considerations will be provided on the webcast.
Notable announcements in the quarter:
The information contained in this section should be read together with Johnson & Johnson’s other disclosures filed with the Securities and Exchange Commission, including its Current Reports on Form 8-K, Quarterly Reports on Form 10-Q and Annual Reports on Form 10-K. Copies of these filings are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson. The reader is also encouraged to review all other news releases and information available in the Investor Relations section of the company’s website at News Releases, as well as Innovative Medicine News Center, MedTech News & Events, and www.factsabouttalc.com.
Regulatory
European Commission approves subcutaneous RYBREVANT (amivantamab) for the treatment of patients with advanced EGFR-mutated non-small cell lung cancer1
Press Release
European Commission approves Johnson & Johnson’s subcutaneous DARZALEX (daratumumab)-based quadruplet regimen for the treatment of patients with newly diagnosed multiple myeloma, regardless of transplant eligibility1
Press Release
U.S. FDA approves TREMFYA (guselkumab), the first and only IL-23 inhibitor offering both subcutaneous and intravenous induction options, for adult patients with moderately to severely active Crohn's disease
Press Release
Nipocalimab, the first and only investigational treatment to be granted U.S. FDA Breakthrough Therapy designation for the treatment of adults with moderate-to-severe Sjögren's disease, has now received Fast Track designation
Press Release
Data Releases
Johnson & Johnson MedTech Announces Completion of First Cases with OTTAVA Robotic Surgical System1
Press Release
Icotrokinra results show 75% of adolescents with plaque psoriasis achieved completely clear skin and demonstrate favorable safety profile in a once daily pill1
Press Release
Johnson & Johnson highlights new data that showcase the strength of nipocalimab, demonstrating long-term sustained disease control in adults living with generalized myasthenia gravis (gMG)1
Press Release
TREMFYA (guselkumab) is the first and only IL-23 inhibitor to significantly reduce both the signs and symptoms and the progression of structural damage in adults living with active psoriatic arthritis1
Press Release
Johnson & Johnson MedTech to Highlight Latest Advancements in Heart Disease Treatment with Impella at ACC.25
Press Release
RYBREVANT (amivantamab-vmjw) plus LAZCLUZE (lazertinib) outperforms osimertinib with a significant and unprecedented overall survival benefit in patients with EGFR-mutated non-small cell lung cancer
Press Release
New nipocalimab data and real-world research at AAN 2025 highlight positive Phase 3 results and commitment to people living with generalized myasthenia gravis (gMG)
Press Release
RYBREVANT (amivantamab-vmjw) plus LAZCLUZE (lazertinib) significantly outperforms standard of care in first-line EGFR-mutated lung cancer with compelling new data at ELCC 2025
Press Release
Johnson & Johnson MedTech Showcases New Era of Digital Orthopaedics at AAOS 2025
Press Release
Icotrokinra meets primary endpoint of clinical response in ulcerative colitis study and shows potential to transform the treatment paradigm for patients
Press Release
Icotrokinra results show potential to set a new standard of treatment in plaque psoriasis
Press Release
TREMFYA (guselkumab) subcutaneous (SC) induction data support potential to be the first and only in its class to offer the option of both intravenous and SC induction therapy in ulcerative colitis
Press Release
New nipocalimab data published in mAbs journal details differentiated molecular design, clinical profile and potential of nipocalimab to treat IgG-driven alloantibody and autoantibody diseases
Press Release
Findings from pivotal nipocalimab Phase 3 study in a broad antibody positive population of people living with generalized myasthenia gravis (gMG) published in The Lancet Neurology
Press Release
Product Launch
Shockwave Medical Launches Novel Forward Intravascular Lithotripsy Platform in U.S. to Transform Treatment of Difficult-to-Cross Calcified Lesions
Press Release
Other
Johnson & Johnson Closes Landmark Intra-Cellular Therapies, Inc. Acquisition to Solidify Neuroscience Leadership1
Press Release
Johnson & Johnson to Return to Tort System to Defeat Meritless Talc Claims1
Press Release
Johnson & Johnson Increases U.S. Investment to More than $55 Billion Over the Next Four Years
Press Release
Johnson & Johnson Announces Darren Snellgrove as Vice President, Investor Relations
Press Release
Webcast information:
Johnson & Johnson will conduct a conference call with investors to discuss this earnings release today at 8:30 a.m., Eastern Time. A simultaneous webcast of the call for investors and other interested parties may be accessed by visiting the Johnson & Johnson website. A replay and podcast will be available approximately two hours after the live webcast in the Investor Relations section of the company's website at events-and-presentations.
About Johnson & Johnson:
At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow, and profoundly impact health for humanity. Learn more at www.jnj.com.
Non-GAAP financial measures:
* “Operational sales growth” excluding the impact of translational currency, “adjusted operational sales growth” excluding the net impact of acquisitions and divestitures and translational currency, as well as “adjusted net earnings”, “adjusted diluted earnings per share” and “adjusted operational diluted earnings per share” excluding after-tax intangible amortization expense and special items, are non-GAAP financial measures and should not be considered replacements for, and should be read together with, the most comparable GAAP financial measures. Except for guidance measures, reconciliations of these non-GAAP financial measures to the most directly comparable GAAP financial measures can be found in the accompanying financial schedules of the earnings release and the Investor Relations section of the company's website at quarterly results.
Copies of the financial schedules accompanying this earnings release are available on the company’s website at quarterly results. These schedules include supplementary sales data, a condensed consolidated statement of earnings, reconciliations of non-GAAP financial measures, and sales of key products/franchises. Additional information on Johnson & Johnson, including adjusted income before tax by segment, an Innovative Medicine pipeline of selected compounds in late stage development and a copy of today’s earnings call presentation can also be found in the Investor Relations section of the company's website at quarterly results.
Note to investors concerning forward-looking statements:
This press release contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 regarding, among other things: future operating and financial performance, product development, and market position and business strategy. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson & Johnson. Risks and uncertainties include, but are not limited to: economic factors, such as interest rate and currency exchange rate fluctuations or changes to applicable laws and regulations; competition, including technological advances, new products and patents attained by competitors; challenges inherent in new product research and development, including uncertainty of clinical success and obtaining regulatory approvals; uncertainty of commercial success for new and existing products; challenges to patents; the impact of patent expirations; the ability of the Company to successfully execute strategic plans, including restructuring plans; the impact of business combinations and divestitures; manufacturing difficulties or delays, internally or within the supply chain; product efficacy or safety concerns resulting in product recalls or regulatory action; significant adverse litigation or government action, including related to product liability claims; changes to applicable laws and regulations, including tax laws and global health care reforms; trends toward health care cost containment; changes in behavior and spending patterns of purchasers of health care products and services; financial instability of international economies and legal systems and sovereign risk; and increased scrutiny of the health care industry by government agencies. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson’s most recent Annual Report on Form 10-K, including in the sections captioned “Cautionary Note Regarding Forward-Looking Statements” and “Item 1A. Risk Factors,” and in Johnson & Johnson’s subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson. Any forward-looking statement made in this release speaks only as of the date of this release. Johnson & Johnson does not undertake to update any forward-looking statement as a result of new information or future events or developments.
Percent Change
2025
2024
Total
Operations
Currency
$
8,092
7,612
6.3
%
6.3
-
5,781
5,950
(2.9
)
1.5
(4.4
)
13,873
13,562
2.3
4.2
(1.9
)
4,213
4,008
5.1
5.1
-
3,807
3,813
(0.2
)
3.0
(3.2
)
8,020
7,821
2.5
4.1
(1.6
)
12,305
11,620
5.9
5.9
-
9,588
9,763
(1.8
)
2.1
(3.9
)
$
21,893
21,383
2.4
%
4.2
(1.8
)
Percent Change
2025
2024
Total
Operations
Currency
$
12,305
11,620
5.9
%
5.9
-
5,110
5,163
(1.0
)
2.2
(3.2
)
1,167
1,194
(2.3
)
9.2
(11.5
)
3,311
3,406
(2.8
)
(0.6
)
(2.2
)
9,588
9,763
(1.8
)
2.1
(3.9
)
$
21,893
21,383
2.4
%
4.2
(1.8
)
2025
2024
Percent
Percent
Percent
Increase
Amount
to Sales
Amount
to Sales
(Decrease)
$
21,893
100.0
$
21,383
100.0
2.4
7,357
33.6
6,511
30.4
13.0
14,536
66.4
14,872
69.6
(2.3
)
5,112
23.3
5,257
24.6
(2.8
)
3,225
14.7
3,542
16.6
(8.9
)
(128
)
(0.6
)
(209
)
(1.0
)
(7,321
)
(33.4
)
2,404
11.2
17
0.1
164
0.8
13,631
62.3
3,714
17.4
267.0
2,632
12.1
459
2.2
473.4
$
10,999
50.2
$
3,255
15.2
237.9
$
4.54
$
1.34
238.8
2,423.8
2,430.1
19.3
%
12.4
%
$
8,011
36.6
$
7,877
36.8
1.7
$
6,706
30.6
$
6,580
30.8
1.9
$
2.77
$
2.71
2.2
16.3
%
16.5
%
2025
2024
$10,999
$3,255
(6,966)
2,726
1,120
1,078
55
171
132
148
39
(20)
-
51
-
9
1,315
(856)
12
18
$6,706
$6,580
2,423.8
2,430.1
$2.77
$2.71
$2.81
1
2
2.3%
2.5%
2.4%
6.3%
5.1%
5.9%
(2.9)%
(0.2)%
(1.8)%
(1.9)
(1.6)
(1.8)
-
-
-
(4.4)
(3.2)
(3.9)
4.2%
4.1%
4.2%
6.3%
5.1%
5.9%
1.5%
3.0%
2.1%
(3.3)
(1.2)
(5.1)
(1.8)
(1.4)
(0.5)
0.2
0.5
0.3
0.0
0.9
0.3
0.4
0.2
0.3
4.4%
1.3%
3.3%
6.3%
0.9%
4.4%
1.9%
1.8%
1.9%
REPORTED SALES vs. PRIOR PERIOD ($MM)
2025
2024
Reported
Operational (1)
Currency
$ 3,013
2,383
26.4
%
26.4
%
-
2,664
2,430
9.6
%
14.4
%
-4.8
%
5,678
4,814
17.9
%
20.4
%
-2.5
%
318
140
*
*
-
51
16
*
*
*
369
157
*
*
*
1,829
1,464
24.9
%
24.9
%
-
1,409
1,228
14.7
%
19.8
%
-5.1
%
3,237
2,692
20.3
%
22.5
%
-2.2
%
292
285
2.5
%
2.5
%
-
479
404
18.5
%
23.1
%
-4.6
%
771
689
11.9
%
14.6
%
-2.7
%
235
265
-11.5
%
-11.5
%
-
474
518
-8.5
%
-4.2
%
-4.3
%
709
784
-9.5
%
-6.7
%
-2.8
%
113
36
*
*
-
28
11
*
*
*
141
47
*
*
*
68
50
35.2
%
35.2
%
-
18
8
*
*
*
86
58
48.4
%
50.2
%
-1.8
%
105
101
4.9
%
4.9
%
-
46
33
38.8
%
45.9
%
-7.1
%
151
133
13.3
%
15.0
%
-1.7
%
7
9
-24.3
%
-24.3
%
-
118
172
-31.3
%
-28.5
%
-2.8
%
125
181
-30.9
%
-28.3
%
-2.6
%
47
33
42.9
%
42.9
%
-
42
41
4.6
%
10.1
%
-5.5
%
89
73
21.7
%
24.7
%
-3.0
%
REPORTED SALES vs. PRIOR PERIOD ($MM)
2025
2024
Reported
Operational (1)
Currency
2,196
2,453
-10.5
%
-10.5
%
-
1,510
1,794
-15.8
%
-11.5
%
-4.3
%
3,707
4,247
-12.7
%
-10.9
%
-1.8
%
314
266
18.1
%
18.1
%
-
10
27
-64.2
%
-64.2
%
-
143
141
1.3
%
6.8
%
-5.5
%
467
434
7.5
%
9.3
%
-1.8
%
292
254
14.8
%
14.8
%
-
366
299
22.4
%
29.7
%
-7.3
%
659
554
18.9
%
22.9
%
-4.0
%
981
1,396
-29.8
%
-29.8
%
-
644
1,055
-38.9
%
-35.8
%
-3.1
%
1,625
2,451
-33.7
%
-32.3
%
-1.4
%
599
509
17.6
%
17.6
%
-
356
299
19.2
%
24.4
%
-5.2
%
956
808
18.2
%
20.1
%
-1.9
%
1
0
*
*
-
0
0
-
-
-
1
0
*
*
-
968
1,054
-8.1
%
-8.1
%
-
679
749
-9.3
%
-5.5
%
-3.8
%
1,647
1,803
-8.6
%
-7.0
%
-1.6
%
38
41
-7.4
%
-7.4
%
-
110
136
-18.9
%
-15.2
%
-3.7
%
148
177
-16.3
%
-13.4
%
-2.9
%
625
765
-18.2
%
-18.2
%
-
277
292
-4.9
%
-1.1
%
-3.8
%
903
1,056
-14.5
%
-13.5
%
-1.0
%
276
191
45.0
%
45.0
%
-
43
34
25.0
%
31.7
%
-6.7
%
320
225
41.9
%
42.9
%
-1.0
%
28
58
-50.6
%
-50.6
%
-
248
287
-13.4
%
-9.8
%
-3.6
%
277
345
-19.6
%
-16.7
%
-2.9
%
REPORTED SALES vs. PRIOR PERIOD ($MM)
2025
2024
Reported
Operational (1)
Currency
744
766
-2.9
%
-2.9
%
-
281
283
-0.6
%
3.2
%
-3.8
%
1,025
1,049
-2.3
%
-1.2
%
-1.1
%
363
356
2.1
%
2.1
%
-
159
169
-6.0
%
-2.5
%
-3.5
%
522
524
-0.5
%
0.6
%
-1.1
%
365
392
-6.9
%
-6.9
%
-
86
76
13.4
%
17.5
%
-4.1
%
451
468
-3.6
%
-2.9
%
-0.7
%
15
18
-12.7
%
-12.7
%
-
37
39
-4.6
%
-0.3
%
-4.3
%
52
56
-7.2
%
-4.3
%
-2.9
%
315
324
-2.8
%
-2.8
%
-
487
497
-1.9
%
1.9
%
-3.8
%
802
821
-2.2
%
0.1
%
-2.3
%
8
8
-1.3
%
-1.3
%
-
350
315
11.0
%
14.7
%
-3.7
%
358
323
10.7
%
14.3
%
-3.6
%
305
314
-2.9
%
-2.9
%
-
98
104
-6.2
%
-0.6
%
-5.6
%
403
418
-3.7
%
-2.3
%
-1.4
%
2
2
7.7
%
7.7
%
-
39
77
-48.8
%
-47.0
%
-1.8
%
41
78
-47.6
%
-45.9
%
-1.7
%
855
631
35.4
%
35.4
%
-
158
197
-19.7
%
-15.3
%
-4.4
%
1,013
829
22.3
%
23.4
%
-1.1
%
690
518
33.3
%
33.3
%
-
-
-
-
-
-
690
518
33.3
%
33.3
%
-
165
114
45.0
%
45.0
%
-
158
197
-19.7
%
-15.3
%
-4.4
%
323
311
3.9
%
6.7
%
-2.8
%
8,092
7,612
6.3
%
6.3
%
-
5,781
5,950
-2.9
%
1.5
%
-4.4
%
$ 13,873
13,562
2.3
%
4.2
%
-1.9
%
REPORTED SALES vs. PRIOR PERIOD ($MM)
FIRST QUARTER
% Change
2025
2024
Reported
Operational (1)
Currency
$ 1,261
1,025
23.0
%
23.0
%
-
842
781
7.8
%
10.7
%
-2.9
%
2,103
1,806
16.4
%
17.7
%
-1.3
%
684
692
-1.1
%
-1.1
%
-
638
652
-2.0
%
0.7
%
-2.7
%
1,323
1,344
-1.6
%
-0.2
%
-1.4
%
339
303
11.9
%
11.9
%
-
81
67
19.7
%
23.6
%
-3.9
%
420
371
13.3
%
14.0
%
-0.7
%
206
-
*
*
-
52
-
*
*
-
258
-
*
*
-
32
30
7.1
%
7.1
%
-
72
62
15.1
%
17.4
%
-2.3
%
103
92
12.5
%
14.1
%
-1.6
%
1,384
1,448
-4.4
%
-4.4
%
-
857
892
-3.9
%
-0.9
%
-3.0
%
2,241
2,340
-4.2
%
-3.1
%
-1.1
%
263
270
-2.5
%
-2.5
%
-
146
152
-4.0
%
-0.8
%
-3.2
%
409
422
-3.1
%
-1.9
%
-1.2
%
231
242
-4.3
%
-4.3
%
-
158
160
-1.0
%
2.1
%
-3.1
%
389
401
-3.0
%
-1.7
%
-1.3
%
502
504
-0.5
%
-0.5
%
-
270
261
3.7
%
7.2
%
-3.5
%
772
765
0.9
%
2.1
%
-1.2
%
388
432
-10.2
%
-10.2
%
-
283
320
-11.6
%
-8.9
%
-2.7
%
671
752
-10.8
%
-9.7
%
-1.1
%
REPORTED SALES vs. PRIOR PERIOD ($MM)
FIRST QUARTER
% Change
2025
2024
Reported
Operational (1)
Currency
1,002
987
1.5
%
1.5
%
-
1,394
1,429
-2.5
%
0.8
%
-3.3
%
2,396
2,416
-0.8
%
1.1
%
-1.9
%
457
446
2.7
%
2.7
%
-
616
641
-4.0
%
-1.0
%
-3.0
%
1,073
1,087
-1.2
%
0.5
%
-1.7
%
544
542
0.5
%
0.5
%
-
778
788
-1.2
%
2.3
%
-3.5
%
1,323
1,330
-0.5
%
1.6
%
-2.1
%
566
547
3.4
%
3.4
%
-
713
710
0.4
%
3.9
%
-3.5
%
1,279
1,258
1.7
%
3.7
%
-2.0
%
452
438
3.1
%
3.1
%
-
467
472
-1.1
%
2.4
%
-3.5
%
919
910
1.0
%
2.7
%
-1.7
%
114
110
4.3
%
4.3
%
-
246
238
3.4
%
7.1
%
-3.7
%
361
348
3.7
%
6.2
%
-2.5
%
4,213
4,008
5.1
%
5.1
%
-
3,807
3,813
-0.2
%
3.0
%
-3.2
%
$ 8,020
7,821
2.5
%
4.1
%
-1.6
%
2023
2024
2024
Full Year
Q1
Q2
Q3
Q4
Full Year
66
36
52
68
101
257
27
11
17
21
21
70
93
47
69
89
122
327
56
50
59
64
68
241
7
8
9
12
17
46
63
58
69
75
85
287
93
33
37
36
39
145
235
41
45
50
36
172
328
73
83
86
75
317
1,292
356
376
417
408
1,557
681
169
171
166
162
668
1,973
524
548
583
570
2,225
79
18
17
21
19
75
182
39
49
39
38
165
260
56
67
60
57
240
19
2
5
3
1
11
1,395
77
227
54
43
401
1,414
78
233
56
45
412
First Quarter March 30, 2025 GAAP
Intangible asset amortization
Litigation related
Restructuring related
Acquisition, integration and divestiture related
(Loss)/gain on securities
Tax legislation and other tax related
First Quarter March 30, 2025 Non-GAAP
$
4,020
(649
)
3,371
2,261
2,261
2,548
2,548
(166
)
-
-
-
(20
)
(18
)
-
(204
)
5,210
649
-
-
20
18
-
5,897
First Quarter March 30, 2025 GAAP
Intangible asset amortization
Litigation related
Restructuring related
Acquisition, integration and divestiture related
(Loss)/gain on securities
Tax legislation and other tax related
First Quarter March 30, 2025 Non-GAAP
$
3,326
(471
)
(8
)
(52
)
2,795
2,656
2,656
677
(6
)
671
(60
)
-
-
(47
)
(54
)
(21
)
-
(182
)
1,421
471
-
55
112
21
-
2,080
First Quarter March 30, 2025 GAAP
Intangible asset amortization
Litigation related
Restructuring related
Acquisition, integration and divestiture related
(Loss)/gain on securities
Tax legislation and other tax related
First Quarter March 30, 2025 Non-GAAP
$
11
11
195
195
-
(7,206
)
-
6,966
-
-
-
-
(240
)
7,000
-
(6,966
)
-
-
-
-
34
First Quarter March 30, 2025 GAAP
Intangible asset amortization
Litigation related
Restructuring related
Acquisition, integration and divestiture related
(Loss)/gain on securities
Tax legislation and other tax related
First Quarter March 30, 2025 Non-GAAP
$
7,357
(1,120
)
(8
)
(52
)
-
6,177
5,112
5,112
3,225
(6
)
3,219
(7,321
)
-
6,966
(30
)
(74
)
(39
)
(498
)
-
-
(128
)
(128
)
17
(17
)
-
13,631
1,120
(6,966
)
55
132
39
-
8,011
2,632
188
(1,553
)
11
30
9
(12
)
1,305
10,999
932
(5,413
)
44
102
30
12
6,706
$
3,370
(698
)
(2
)
2,670
2,438
2,438
2,896
(7
)
2,889
(111
)
(144
)
(47
)
55
(247
)
4,969
698
-
144
47
(55
)
-
9
-
5,812
$
3,120
(380
)
(7
)
(20
)
2,713
2,582
(4
)
2,578
646
(18
)
(27
)
601
(47
)
(20
)
(43
)
(22
)
(132
)
1,520
380
-
27
61
22
51
-
-
2,061
$
21
21
237
237
-
-
2,517
(2,726
)
(40
)
(13
)
(262
)
(2,775
)
-
2,726
-
40
13
-
-
-
4
$
6,511
(1,078
)
(7
)
(20
)
(2
)
5,404
5,257
(4
)
5,253
3,542
(18
)
(27
)
(7
)
3,490
2,404
(2,726
)
(130
)
20
(432
)
-
-
(209
)
(209
)
164
(164
)
-
3,714
1,078
2,726
171
148
(20
)
51
9
-
7,877
459
148
627
39
38
(7
)
9
2
(18
)
1,297
3,255
930
2,099
132
110
(13
)
42
7
18
6,580
Media contact: media-relations@its.jnj.com
Investor contact: investor-relations@its.jnj.com
